Key facts
- This page summarizes PERCEPTIVE ADVISORS LLC's Form 4 filing for VYNE Therapeutics Inc. (VYNE).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 18 Aug 2021, 19:19.
PERCEPTIVE ADVISORS LLC - 16 Aug 2021 Form 4 Insider Report for VYNE Therapeutics Inc. (VYNE)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- VYNE
- Reported as of
- 16 Aug 2021
- Net transaction value
- -$435,000
- SEC form
- 4
- Accepted by SEC
- 18 Aug 2021, 19:19:37 UTC
- Prior SEC filing
- 17 Aug 2021
- Next SEC filing
- 19 Aug 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joseph Edelman - for Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its investment manager, By: Joseph Edelman, its managing member
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
PERCEPTIVE ADVISORS LLC filed Form 4 for VYNE Therapeutics Inc. (VYNE) on 18 Aug 2021.
Change
- Previous filing in this sequence was filed on 17 Aug 2021.
- Current net transaction value: -$435,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VYNE
transaction
Common Stock
Sale
- Transaction value
- $435,000
- Shares
- -250,000
- Change %
- -4.8%
- Price
- $1.74
- Shares after
- 4,935,057
- Date
- 16 Aug 2021
- Ownership
- See Footnote
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
PERCEPTIVE ADVISORS LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.82, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.
Footnote F2
The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.